Related Experiment Video
Updated: Jun 11, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Biosimilars: pharmacovigilance and risk management.
1Faculty of Pharmacy, Pharmaceutical Technology Department, University of the Basque Country, Vitoria-Gasteiz, Spain.
Pharmacoepidemiology and Drug Safety
|June 29, 2010
Summary
Biosimilar medicines require rigorous post-approval safety monitoring due to potential differences from reference biologics. Ongoing pharmacovigilance and risk management are crucial for ensuring patient safety and a favorable benefit-risk profile.
Area of Science:
- Pharmacovigilance and Drug Safety
- Biopharmaceutical Regulation
- Risk Management in Healthcare
Background:
- Biosimilars, while similar in efficacy to reference biologics, may present different safety profiles.
- Pre-authorization studies often lack sufficient data to identify all potential safety variations.
- Continuous post-approval monitoring is essential for assessing the safety of similar biological medicinal products.
Purpose of the Study:
- To highlight the necessity of robust post-approval safety surveillance for biosimilars.
- To emphasize the role of risk management plans in identifying and mitigating potential safety issues.
- To discuss the importance of comprehensive product identification for biologicals.
Main Methods:
- Review of regulatory requirements for biosimilar authorization and post-approval safety.
- Analysis of the critical role of risk management plans (EU-RMP) and pharmacovigilance programs.
- Discussion of immunogenicity as a key safety concern for biopharmaceuticals.
- Examination of product identification strategies for biologicals.
Main Results:
- Biosimilars necessitate distinct authorization pathways and ongoing safety evaluations compared to generics.
- Risk management plans must proactively address potential safety concerns, including immunogenicity.
- Enhanced pharmacovigilance and post-marketing surveillance are critical for biosimilars.
- Standardized International Nonproprietary Names (INNs) alone are insufficient for unique biological product identification.
Conclusions:
- Rigorous, ongoing clinical safety monitoring is imperative for biosimilars post-authorization.
- Comprehensive risk management strategies, focusing on immunogenicity and pharmacovigilance, are vital.
- Clear product identification, including brand names or manufacturer details alongside INNs, is essential for global safety surveillance.
Related Concept Videos
01:19Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:28Biopharmaceutics and Pharmacokinetics: Overview
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the appropriate...